Neuphoria Therapeutics Inc.
USD3.42
-0.12 (-3.26%)
CEO
Spyridon Papapetropoulos
IPO Date
2021-12-16
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Open
$3.50
Prev. Close
$3.53
Day Low
$3.39
Day High
$3.62
52W Low
$3.19
52W High
$21.40
Market Cap
$0.02B
Volume
0.05M
| 8,537 |
| $0.00 |
| 21 Jan 2026 | Fisher Alan | director | A-Award | Acquired | 17,073 | $0.00 |
| 21 Jan 2026 | Ryan Jane | director | A-Award | Acquired | 8,537 | $0.00 |
| 23 Oct 2025 | Lynx1 Capital Management LP | 10 percent owner | P-Purchase | Acquired | 639,110 | $5.14 |
| 23 Oct 2025 | Lynx1 Capital Management LP | 10 percent owner | Disposed | 0 | $0.00 |
| 2 Sept 2025 | Papapetropoulos Spyros | director, officer: President and CEO | A-Award | Acquired | 34,559 | $8.27 |
| 19 May 2025 | Papapetropoulos Spyros | director, officer: President and CEO | A-Award | Acquired | 27,000 | $5.16 |
| 18 Apr 2025 | Papapetropoulos Spyros | director, officer: President and CEO | A-Award | Acquired | 270,000 | $5.16 |